Drugs / PRO95780
last change Sep 2010 re-read 2 minutes ago

PRO95780

Developed for
colorectal cancer · chondrosarcoma · non-Hodgkin lymphoma · non-small cell lung carcinoma
Investigated by
Genentech, Inc.

Trials 5 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT00851136 May 2009 → Jun 2010 colorectal cancer Genentech, Inc. Completed No outcome recorded
Phase 1 NCT00497497 Oct 2007 → Sep 2010 colorectal cancer Genentech, Inc. Completed No outcome recorded
Phase 23 trials
Phase 2 NCT00517049 Mar 2008 → Dec 2009 non-Hodgkin lymphoma Genentech, Inc. Completed No outcome recorded
Phase 2 NCT00480831 Jun 2007 → Aug 2010 non-small cell lung carcinoma Genentech, Inc. Completed No outcome recorded
Phase 2 NCT00543712 May 2007 → May 2008 chondrosarcoma Genentech, Inc. Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as PRO95780 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00480831
4

NCT00517049

NCT00543712

NCT00851136

NCT00497497

Route Intravenous Intravenous repeating dose” NCT00480831